ProfileGDS5678 / 1417972_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 80% 80% 83% 81% 74% 69% 80% 83% 81% 79% 81% 82% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7210681
GSM967853U87-EV human glioblastoma xenograft - Control 25.7527380
GSM967854U87-EV human glioblastoma xenograft - Control 35.6382880
GSM967855U87-EV human glioblastoma xenograft - Control 46.225683
GSM967856U87-EV human glioblastoma xenograft - Control 55.879181
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7143174
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3195169
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6248480
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0139583
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8970281
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4979979
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8648781
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9638682
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8799382